Education
About Us
Working with TipRanks
Follow Us
Geron Corporation (GERN)
:GERN
GERN Analyst Ratings
Moderate Buy
5 Buy
2 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GERN Stock 12 Month Forecast
Average Price Target
$3.50
▲(191.67% Upside)
| Highest Price Target$6.00 | Average Price Target$3.50 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$1
Hold
-16.67%
Downside
Reiterated
08/06/25
Geron's overall stock score reflects significant financial challenges, with ongoing losses and negative cash flows weighing heavily. While the earnings call provided positive insights into revenue growth and strategic expansions, the technical indicators and valuation concerns highlight persistent market skepticism.
Leerink Partners
$3
Buy
150.00%
Upside
Reiterated
07/21/25
Cautiously Optimistic: Geron's Strategic Changes and Growth Prospects Support Buy RatingWe estimate $50.5M Rytelo net revenues for the quarter, slightly above FactSet consensus of $48M. We think commentary on the Rytelo launch trajectory will be important, notably the potential impact in 2H25 of the expanded field force and what else management is doing to bolster a launch that is now at its 1-year mark. The outlook for Rytelo in lower-risk myelodysplastic syndromes (LR-MDS) continues to be hotly debated. Bulls argue the drug fills a need in a large indication and the launch issues are fixable. Bears argue the drug is severely handicapped by toxicity issues and a broken launch. We fall somewhere in-between, acknowledging that the drug's role appears to be less than initial lofty expectations held by us and others while also noting GERN's current valuation underwrites little growth from here.
Barclays
$4
Buy
233.33%
Upside
Reiterated
07/21/25
Goldman Sachs
$1
Sell
-16.67%
Downside
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
TD Cowen
$4
Buy
233.33%
Upside
Reiterated
05/12/25
Scotiabank
$4→$1.5
Hold
25.00%
Upside
Downgraded
05/08/25
Wedbush
$7→$6
Buy
400.00%
Upside
Reiterated
05/08/25
H.C. Wainwright
―
Hold
―
Reiterated
05/07/25
Needham
$5
Buy
316.67%
Upside
Reiterated
05/07/25
Stifel Nicolaus
$4
Buy
233.33%
Upside
Reiterated
03/12/25
B.Riley Financial
$3.5→$2
Hold
66.67%
Upside
Downgraded
02/26/25
Cantor Fitzgerald
$9
Buy
650.00%
Upside
Assigned
11/08/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$1
Hold
-16.67%
Downside
Reiterated
08/06/25
Geron's overall stock score reflects significant financial challenges, with ongoing losses and negative cash flows weighing heavily. While the earnings call provided positive insights into revenue growth and strategic expansions, the technical indicators and valuation concerns highlight persistent market skepticism.
Leerink Partners
$3
Buy
150.00%
Upside
Reiterated
07/21/25
Cautiously Optimistic: Geron's Strategic Changes and Growth Prospects Support Buy RatingWe estimate $50.5M Rytelo net revenues for the quarter, slightly above FactSet consensus of $48M. We think commentary on the Rytelo launch trajectory will be important, notably the potential impact in 2H25 of the expanded field force and what else management is doing to bolster a launch that is now at its 1-year mark. The outlook for Rytelo in lower-risk myelodysplastic syndromes (LR-MDS) continues to be hotly debated. Bulls argue the drug fills a need in a large indication and the launch issues are fixable. Bears argue the drug is severely handicapped by toxicity issues and a broken launch. We fall somewhere in-between, acknowledging that the drug's role appears to be less than initial lofty expectations held by us and others while also noting GERN's current valuation underwrites little growth from here.
Barclays
$4
Buy
233.33%
Upside
Reiterated
07/21/25
Goldman Sachs
$1
Sell
-16.67%
Downside
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
TD Cowen
$4
Buy
233.33%
Upside
Reiterated
05/12/25
Scotiabank
$4→$1.5
Hold
25.00%
Upside
Downgraded
05/08/25
Wedbush
$7→$6
Buy
400.00%
Upside
Reiterated
05/08/25
H.C. Wainwright
―
Hold
―
Reiterated
05/07/25
Needham
$5
Buy
316.67%
Upside
Reiterated
05/07/25
Stifel Nicolaus
$4
Buy
233.33%
Upside
Reiterated
03/12/25
B.Riley Financial
$3.5→$2
Hold
66.67%
Upside
Downgraded
02/26/25
Cantor Fitzgerald
$9
Buy
650.00%
Upside
Assigned
11/08/24
Best Analysts Covering Geron
1 Month
xxx
Success Rate
6/12 ratings generated profit
Average Return
+8.43%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +8.43% per trade.
3 Months
xxx
Success Rate
13/26 ratings generated profit
Average Return
+3.98%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +3.98% per trade.
1 Year
2 Years
xxx
Success Rate
8/26 ratings generated profit
Average Return
-10.53%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -10.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GERN Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
16
14
13
9
8
Buy
4
1
0
0
0
Hold
6
5
6
8
8
Sell
0
0
0
0
2
Strong Sell
0
0
0
0
0
total
26
20
19
17
18
Each month's total comprises the sum of three months' worth of ratings.
GERN Financial Forecast
GERN Stock Forecast FAQ
What is GERN’s average 12-month price target, according to analysts?
Based on analyst ratings, Geron Corporation’s 12-month average price target is 3.50.
What is GERN’s upside potential, based on the analysts’ average price target?
Geron Corporation has 191.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GERN a Buy, Sell or Hold?
Geron Corporation has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.
What is Geron Corporation’s price target?
The average price target for Geron Corporation is 3.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $1.00. The average price target represents 191.67% Increase from the current price of $1.2.
The highest analyst price target is $6.00 ,the lowest forecast is $1.00. The average price target represents 191.67% Increase from the current price of $1.2.
What do analysts say about Geron Corporation?
Geron Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of GERN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.